NASDAQ:ABOS Acumen Pharmaceuticals (ABOS) Stock Forecast, Price & News $4.93 -0.01 (-0.20%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$4.77▼$4.9950-Day Range$3.59▼$6.5952-Week Range$3.16▼$10.97Volume64,973 shsAverage Volume136,882 shsMarket Capitalization$202.28 millionP/E RatioN/ADividend YieldN/APrice Target$15.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acumen Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside219.5% Upside$15.75 Price TargetShort InterestHealthy0.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.22Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.30) to ($1.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector331st out of 1,006 stocksBiological Products, Except Diagnostic Industry44th out of 167 stocks 3.5 Analyst's Opinion Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.75, Acumen Pharmaceuticals has a forecasted upside of 219.5% from its current price of $4.93.Amount of Analyst CoverageAcumen Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.58% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently decreased by 26.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABOS. Previous Next 2.9 News and Social Media Coverage News SentimentAcumen Pharmaceuticals has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acumen Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest19 people have searched for ABOS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 4 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Acumen Pharmaceuticals is held by insiders.Percentage Held by Institutions67.92% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.30) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acumen Pharmaceuticals is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acumen Pharmaceuticals is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Acumen Pharmaceuticals (NASDAQ:ABOS) StockAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Read More Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ABOS Stock News HeadlinesMay 28, 2023 | americanbankingnews.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 26.3% in MayMay 24, 2023 | americanbankingnews.comAcumen Pharmaceuticals, Inc. Expected to Post FY2023 Earnings of ($1.13) Per Share (NASDAQ:ABOS)June 1, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 19, 2023 | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) Receives New Coverage from Analysts at Cantor FitzgeraldMay 18, 2023 | msn.comCantor Fitzgerald Initiates Coverage of Acumen Pharmaceuticals (ABOS) with Overweight RecommendationMay 16, 2023 | finance.yahoo.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call TranscriptMay 14, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increased by AnalystMay 14, 2023 | americanbankingnews.comHead-To-Head Contrast: Acumen Pharmaceuticals (ABOS) & The CompetitionJune 1, 2023 | Behind the Markets (Ad)WARNING to all American InvestorsChina's sneaky plan could wipe out your retirement - in a single morning. Learn how to protect yourself here>>>May 12, 2023 | americanbankingnews.comShort Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Decreases By 63.2%May 9, 2023 | finanznachrichten.deAcumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business HighlightsMay 9, 2023 | finance.yahoo.comAcumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business HighlightsMay 8, 2023 | msn.comEarnings Outlook For Acumen PharmaceuticalsMay 7, 2023 | americanbankingnews.comAcumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on TuesdayMay 4, 2023 | finance.yahoo.comAcumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare ConferenceMay 3, 2023 | msn.comLilly sends Alzheimer’s drug developers higher after trial dataMay 2, 2023 | finance.yahoo.comAcumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023April 24, 2023 | americanbankingnews.comHead to Head Review: Acumen Pharmaceuticals (ABOS) versus Its PeersApril 16, 2023 | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) vs. Cullinan Oncology (NASDAQ:CGEM) Financial SurveyApril 15, 2023 | americanbankingnews.comAcumen Pharmaceuticals (ABOS) and The Competition Head to Head ComparisonApril 9, 2023 | finance.yahoo.comInstitutions own 26% of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares but private equity firms control 42% of the companyApril 4, 2023 | americanbankingnews.comHead to Head Comparison: Acumen Pharmaceuticals (NASDAQ:ABOS) and ZIVO Bioscience (OTCMKTS:ZIVO)April 3, 2023 | markets.businessinsider.comBTIG Remains a Buy on Acumen Pharmaceuticals (ABOS)April 1, 2023 | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) PT Lowered to $13.00 at Credit Suisse GroupApril 1, 2023 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Acumen Pharmaceuticals (NASDAQ:ABOS)March 30, 2023 | americanbankingnews.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expected to Earn Q1 2023 Earnings of ($0.31) Per ShareMarch 29, 2023 | seekingalpha.comAcumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ABOS Company Calendar Last Earnings3/27/2023Today5/31/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABOS CUSIPN/A CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.75 High Stock Price Forecast$22.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+219.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.36% Return on Assets-22.53% Debt Debt-to-Equity RatioN/A Current Ratio16.41 Quick Ratio16.41 Sales & Book Value Annual Sales$1.44 million Price / Sales140.47 Cash FlowN/A Price / Cash FlowN/A Book Value$4.37 per share Price / Book1.13Miscellaneous Outstanding Shares41,030,000Free Float39,097,000Market Cap$202.28 million OptionableNot Optionable Beta-1.56 Key ExecutivesMr. Daniel J. O'Connell M.B.A. (Age 52)CEO, Pres & Director Comp: $801.62kMr. Matt ZugaCFO, Chief Bus. Officer & Corp. Sec.Dr. Eric Siemers M.D. (Age 68)Chief Medical Officer Comp: $460.64kMr. Russell Barton M.S. (Age 64)Chief Operating Officer Mr. Derek M. Meisner Esq. (Age 52)J.D., Chief Legal Officer Ms. Robyn Moxon M.A.Mang. of Corp. & Clinical CommunicationsMs. Julie BockenstetteExec. VP & Head of HRMs. Siew Tin Gan M.S.Assistant VP & Head of Clinical OperationsMs. Janice HitchcockVP & Head of Regulatory AffairsMs. Liean Schenck M.S.VP & Head of CMCMore ExecutivesKey CompetitorsGenfitNASDAQ:GNFTFennec PharmaceuticalsNASDAQ:FENCIkena OncologyNASDAQ:IKNAPoseida TherapeuticsNASDAQ:PSTXSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInstitutional OwnershipGreat Point Partners LLCSold 65,314 shares on 5/16/2023Ownership: 2.563%Hudson Bay Capital Management LPBought 117,000 shares on 5/16/2023Ownership: 0.870%Jane Street Group LLCBought 64,343 shares on 5/16/2023Ownership: 0.182%Susquehanna International Group LLPBought 33,600 shares on 5/16/2023Ownership: 0.000%Squarepoint Ops LLCBought 19,343 shares on 5/16/2023Ownership: 0.047%View All Institutional Transactions ABOS Stock - Frequently Asked Questions Should I buy or sell Acumen Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABOS shares. View ABOS analyst ratings or view top-rated stocks. What is Acumen Pharmaceuticals' stock price forecast for 2023? 4 Wall Street analysts have issued 1 year price targets for Acumen Pharmaceuticals' shares. Their ABOS share price forecasts range from $13.00 to $22.00. On average, they anticipate the company's share price to reach $15.75 in the next year. This suggests a possible upside of 219.5% from the stock's current price. View analysts price targets for ABOS or view top-rated stocks among Wall Street analysts. How have ABOS shares performed in 2023? Acumen Pharmaceuticals' stock was trading at $5.40 at the beginning of the year. Since then, ABOS shares have decreased by 8.7% and is now trading at $4.93. View the best growth stocks for 2023 here. Are investors shorting Acumen Pharmaceuticals? Acumen Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 159,800 shares, a drop of 26.3% from the April 30th total of 216,800 shares. Based on an average daily trading volume, of 168,700 shares, the short-interest ratio is presently 0.9 days. Currently, 0.6% of the shares of the company are short sold. View Acumen Pharmaceuticals' Short Interest. When is Acumen Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our ABOS earnings forecast. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) released its earnings results on Monday, March, 27th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04. When did Acumen Pharmaceuticals IPO? (ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share. What is Acumen Pharmaceuticals' stock symbol? Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS." Who are Acumen Pharmaceuticals' major shareholders? Acumen Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Great Point Partners LLC (2.56%), BlackRock Inc. (1.64%), Commodore Capital LP (0.98%), Hudson Bay Capital Management LP (0.87%), Guardian Point Capital LP (0.32%) and Jane Street Group LLC (0.18%). Insiders that own company stock include John A Stalfort III, Marc Benioff, Nathan B Fountain, Paul B Manning and Sands Capital Global Venture F. View institutional ownership trends. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acumen Pharmaceuticals' stock price today? One share of ABOS stock can currently be purchased for approximately $4.93. How much money does Acumen Pharmaceuticals make? Acumen Pharmaceuticals (NASDAQ:ABOS) has a market capitalization of $202.28 million and generates $1.44 million in revenue each year. The company earns $-42,860,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. How can I contact Acumen Pharmaceuticals? The official website for the company is www.acumenpharm.com. The company can be reached via phone at 434-297-1000 or via email at investors@acumenpharm.com. This page (NASDAQ:ABOS) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.